Insider transactions

EDGAR

INDAPTUS THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–16 of 16

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-03-23 Filed 2026-03-24Lazar David E. Director
S

Open market or private sale of non-derivative or derivative security

Derivative security: Series AA Convertible Non-Redeemable Preferred Stock — underlying Common Stock (3,936,000)
Disposed (D)196,800——103,200Direct (D) No
F1, F2, F3
  • F1 On March 19, 2026, David E. Lazar (the Reporting Person) entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the March 2026 Transaction). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.
  • F2 The Series AA Preferred Stock is convertible at the option of the holder for no additional consideration.
  • F3 The Series AA Preferred Stock is perpetual and therefore has no expiration date.
Open filing 0000921895-26-000788 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-24Lazar David E. Director
S

Open market or private sale of non-derivative or derivative security

Derivative security: Series AAA Convertible Non-Redeemable Preferred Stock — underlying Common Stock (105,000,000)
Disposed (D)700,000——0Direct (D) No
F1, F4, F5
  • F1 On March 19, 2026, David E. Lazar (the Reporting Person) entered into a Securities Purchase Agreement pursuant to which the Reporting Person sold all of his title and interest in (i) all 700,000 shares of Series AAA Preferred Stock (convertible into an aggregate of 105,000,000 shares of the Issuer's common stock) held by the Reporting Person and (ii) 196,800 shares of the Reporting Person's Series AA Preferred Stock (convertible into an aggregate of 3,936,000 shares of the Issuer's common stock), as well as all of the Reporting Person's rights, title and interest in the Series AA Preferred Stock and Series AAA Preferred Stock under a securities purchase agreement dated December 22, 2025 (the March 2026 Transaction). The closing of the March 2026 Transaction occurred on March 23, 2026. Following the March 2026 Transaction, the Reporting Person retained 103,200 shares of Series AA Preferred Stock, convertible into an aggregate of 2,064,000 shares of the Issuer's common stock.
  • F4 The Series AAA Preferred Stock is convertible at the option of the holder for no additional consideration.
  • F5 The Series AAA Preferred Stock is perpetual and therefore has no expiration date.
Open filing 0000921895-26-000788 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27Jabbour Jerome D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option to Buy Common Stock — underlying Common Stock (25,000) — exercise price 2.06
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.
Open filing 0001493152-26-008330 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Warrants (right to buy) — underlying Common Stock (3,033) — exercise price 47.60
Disposed (D)3,033——0Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (right to buy) — underlying Common Stock (3,033) — exercise price 1.75
Acquired (A)3,033——3,033Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Warrants (right to buy) — underlying Common Stock (1,519) — exercise price 29.40
Disposed (D)1,519——0Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (right to buy) — underlying Common Stock (1,519) — exercise price 1.75
Acquired (A)1,519——1,519Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Warrants (right to buy) — underlying Common Stock (12,136) — exercise price 8.30
Disposed (D)12,136——0Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-02-11 Filed 2026-02-13Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Warrants (right to buy) — underlying Common Stock (12,136) — exercise price 1.75
Acquired (A)12,136——12,136Direct (D) No
F1
  • F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Open filing 0001493152-26-006707 Read from the filing’s XML Dispute this row
2026-01-20 Filed 2026-01-22Ben-Tzvi Avraham Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,0000.00
0

Derived: shares × price per share. Exact value 0.00.

25,100Direct (D) No
F1, F2
  • F1 The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant.
  • F2 Includes 100 shares of common stock of the Issuer held in a Roth IRA.
Open filing 0001493152-26-003293 Read from the filing’s XML Dispute this row
2026-01-07 Filed 2026-01-22NATAN DAVID Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option to Buy Common Stock — underlying Common Stock (25,000) — exercise price 2.69
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.
Open filing 0001493152-26-003292 Read from the filing’s XML Dispute this row
2025-12-23 Filed 2026-01-22Ben-Tzvi Avraham Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Option to Buy Common Stock — underlying Common Stock (25,000) — exercise price 1.95
Acquired (A)25,0000.00
0

Derived: shares × price per share. Exact value 0.00.

25,000Direct (D) No
F3
  • F3 The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date.
Open filing 0001493152-26-003293 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-29Newman Michael James Director · Officer: CSO and Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)52,2042.03
105,974.12

Derived: shares × price per share. Exact value 105974.12.

101,074Direct (D) No
F1
  • F1 The Reporting Person acquired 52,204 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.
Open filing 0001493152-25-029354 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-29Sassi Nir Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)26,7582.03
54,318.74

Derived: shares × price per share. Exact value 54318.74.

26,758Direct (D) No
F1
  • F1 The Reporting Person acquired 26,758 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.
Open filing 0001493152-25-029356 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-29Meckler Jeffrey A Director · Officer: Co-Chief Executive Officer · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)216,6172.03
439,732.51

Derived: shares × price per share. Exact value 439732.51.

229,929Direct (D) No
F1
  • F1 The Reporting Person acquired 216,617 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.
Open filing 0001493152-25-029355 Read from the filing’s XML Dispute this row
2025-12-22 Filed 2025-12-29Linscott Walt Addison Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)54,4212.03
110,474.63

Derived: shares × price per share. Exact value 110474.63.

54,426Direct (D) No
F1
  • F1 The Reporting Person acquired 54,421 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.
Open filing 0001493152-25-029353 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–21 of 21

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager195,620 SH449,925 dollarsHigher by 139,150 Prior quarter: 56,470Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 135,978 SH312,749 dollarsHigher by 102,326 Prior quarter: 33,652Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager86,484 SH198,913 dollarsHigher by 32,673 Prior quarter: 53,811Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager83,363 SH191,735 dollarsHigher by 82,885 Prior quarter: 478Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager77,847 SH179,049 dollarsNot in the prior quarter’s filings read Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 72,073 SH165,768 dollarsHigher by 60,487 Prior quarter: 11,586Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 65,315 SH150,225 dollarsHigher by 51,348 Prior quarter: 13,967Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager63,866 SH146,892 dollarsNot in the prior quarter’s filings read Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Virtu Financial LLC Partly reported under another manager34,659 SH80 dollarsNot in the prior quarter’s filings read Open filing 0001533964-26-000015 Filed 2026-11-17 Dispute this row
Jump Financial, LLC Partly reported under another manager27,662 SH63,623 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager27,227 SH62,622 dollarsNot in the prior quarter’s filings read Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
ExodusPoint Capital Management, LP 19,884 SH45,733 dollarsNot in the prior quarter’s filings read Open filing 0001736225-26-000013 Filed 2026-11-16 Dispute this row
Qube Research Technologies Ltd 14,688 SH33,782 dollarsNot in the prior quarter’s filings read Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager14,143 SH32,529 dollarsNot in the prior quarter’s filings read Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
BARCLAYS PLC Partly reported under another manager13,723 SH31,563 dollarsNot in the prior quarter’s filings read Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Balyasny Asset Management L.P. 12,708 SH29,228 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager1,263 SH2,905 dollarsLower by 7,673 Prior quarter: 8,936Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager28 SH80 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
SBI Securities Co., Ltd. 17 SH39 dollarsUnchanged Prior quarter: 17Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
Caitong International Asset Management Co., Ltd 2 SH5 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
CITIGROUP INC Partly reported under another manager1 SH2 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • HRT FINANCIAL LP 206,077 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Sino Lion Ventures Ltd Common Stock, par value $0.01 per share25.32538,895,000.0010/16/2026 Filed 2026-10-22SCHEDULE 13D/AAmendment 3Open filing 0001829126-26-011445 Dispute this row
Chenhao Xu Common Stock, par value $0.01 per share25.32538,895,000.0010/16/2026 Filed 2026-10-22SCHEDULE 13D/AAmendment 3Open filing 0001829126-26-011445 Dispute this row
Yao Yun Common Stock, par value $0.01 per share27.3441,991,000.0010/16/2026 Filed 2026-10-22SCHEDULE 13D/AAmendment 3Open filing 0001829126-26-011443 Dispute this row
Dai Junyi Common Stock, par value $0.01 per share7.32511,250,000.0010/16/2026 Filed 2026-10-22SCHEDULE 13D/AAmendment 3Open filing 0001829126-26-011444 Dispute this row
Yang Ting Common Stock, par value $0.01 per share6.489,948,173.0010/16/2026 Filed 2026-10-21SCHEDULE 13D/AAmendment 3Open filing 0001829126-26-011386 Dispute this row
Yao Yun Common Stock, par value $0.01 per share31.5141,991,000.0006/24/2026 Filed 2026-06-26SCHEDULE 13D/AAmendment 2Open filing 0001829126-26-006949 Dispute this row
Sino Lion Ventures Ltd Common Stock, par value $0.01 per share29.1938,895,000.0006/24/2026 Filed 2026-06-26SCHEDULE 13D/AAmendment 2Open filing 0001829126-26-006953 Dispute this row
Chenhao Xu Common Stock, par value $0.01 per share29.1938,895,000.0006/24/2026 Filed 2026-06-26SCHEDULE 13D/AAmendment 2Open filing 0001829126-26-006953 Dispute this row
Dai Junyi Common Stock, par value $0.01 per share8.4411,250,000.0006/24/2026 Filed 2026-06-26SCHEDULE 13D/AAmendment 2Open filing 0001829126-26-006951 Dispute this row
Yang Ting Common Stock, par value $0.01 per share8.4411,250,000.0006/24/2026 Filed 2026-06-26SCHEDULE 13D/AAmendment 2Open filing 0001829126-26-006950 Dispute this row
Yao Yun Common Stock, $0.01 par value37.141,991,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
SINO LION VENTURES Ltd Common Stock, $0.01 par value34.338,895,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
Xu Chenhao Common Stock, $0.01 par value34.338,895,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
Dai Junyi Common Stock, $0.01 par value9.911,250,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
Yang Ting Common Stock, $0.01 par value9.911,250,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
Deng Lina Common Stock, $0.01 par value4.95,550,000.0004/28/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-004104 Dispute this row
Yao Yun Common Stock, $0.01 par value37.841,991,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
SINO LION VENTURES Ltd Common Stock, $0.01 par value35.038,895,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
Xu Chenhao Common Stock, $0.01 par value35.038,895,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
Dai Junyi Common Stock, $0.01 par value10.111,250,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
Yang Ting Common Stock, $0.01 par value10.111,250,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
Deng Lina Common Stock, $0.01 par value5.05,550,000.0003/23/2026 Filed 2026-03-30SCHEDULE 13DOpen filing 0001829126-26-002858 Dispute this row
Lazar David E. Common Stock, $0.01 par value47.932,064,000.0003/23/2026 Filed 2026-03-24SCHEDULE 13D/AAmendment 1Open filing 0001829126-26-002642 Dispute this row
Lazar David E. Common Stock, $0.01 par value98111,000,000.0002/26/2026 Filed 2026-03-02SCHEDULE 13DOpen filing 0001829126-26-001810 Dispute this row
YA II PN, Ltd. Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
YA Global Investments II (U.S.), LP Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
Yorkville Advisors Global, LP Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
Yorkville Advisors Global II, LLC Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
YAII GP, LP Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
YAII GP II, LLC Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
Mark Angelo Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
SC-Sigma Global Partners, LP Common Stock00.0012/31/2025 Filed 2026-04-06SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-039973 Dispute this row
Jeffery A. Meckler Common Stock, $0.01 par value per share12.7273,103.0012/22/2025 Filed 2025-12-30SCHEDULE 13D/AAmendment 2Open filing 0001493152-25-029594 Dispute this row
Newman Michael James Common Stock, Par Value $0.01 Per Share5.4115,552.0012/22/2025 Filed 2025-12-30SCHEDULE 13D/AAmendment 2Open filing 0001493152-25-029593 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015164,615
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to INDAPTUS THERAPEUTICS, INC.